Answers are grounded in this paper and cite their sources.
Background and Aims: Barrett's esophagus (BE) surveillance is commonly performed to detect early dysplasia and esophageal adenocarcinoma (EAC). However, high-quality incidence rates for the development of dysplasia and EAC in patients with BE are limited. The aim of this study was to perform a systematic review and meta-analysis to provide updated incidence rates for the development of low-grade dysplasia (LGD), high-grade dysplasia (HGD), and EAC in a population of patients with BE undergoing endoscopic surveillance. Methods: We performed a systematic search of Embase and MEDLINE from inception to September 2022. The goal was to identify studies reporting the incidence rates of LGD, EAC, or HGD/EAC as an outcome in patients with nondysplastic BE (NDBE), LGD, or HGD. Respective pooled incidence rates were estimated by using a meta-analysis. Results: Twenty-five studies were included in this meta-analysis comprising 2587 patients with a combined follow-up of 218,351 person-years. For patients with NDBE, pooled incidence rates for progression to LGD, HGD, EAC, and HGD/EAC were 4.29, .52, .21, and .57 per 100 person-years, respectively. For patients with LGD, pooled incidence rates were 3.18 (HGD), 1.16 (EAC), and 5.05 (HGD/EAC) per 100 person-years. For those with HGD, the pooled incidence rate for EAC was 14.16 per 100 person-years. Conclusions: Progression to EAC and HGD/EAC remained low for patients with NDBE. Patients with confirmed (by ≥2 pathologists) LGD may be more likely to develop EAC, prompting a need to assess current BE surveillance strategies in this group.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: